Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685793 | 0.93 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL7936511 | 0.93 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL1636582 | 0.93 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL13336904 | 0.93 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL1636580 | 0.93 | CTSS (0.42) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL13336984 | 0.90 | CTSS (0.36) | ADORA3CHRM1TBXA2RPTGS1CTSS | |
| SCHEMBL4925753 | 0.89 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL13624787 | 0.89 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL16263090 | 0.89 | CYP3A4 (0.47) | CYP3A4 | |
| SCHEMBL3490374 | 0.87 | CYP3A4 (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | ADORA3 3129/4885CHRM1 4876/4885TBXA2R 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.